ÂÜÀòÂÒÂ×

Ishan Shah has a diverse background in scientific research and development. Ishan began their career as a Graduate Teaching Assistant at The University of Toledo in 2009, where they focused on the development and characterization of oil-in-water nanoemulsions for oral drug delivery. Ishan also conducted lipid excipient screening for self-emulsifying properties.

In 2011, Ishan transitioned to The University of Kansas as a Graduate Student Researcher. Ishan'sresearch focused on understanding the role of antibody glycosylation on antibody structure, stability, and Fc-receptor mediated biological functions. This involved characterizing the site-occupancy and site-specific glycosylation of serum IgG using LC-MS/MS and expressing IgGFc and Fc receptors with homogenous glycosylation in yeast cells. Additionally, they investigated the effects of glycosylation on Fc-Fc receptor interactions and the physical stability of antibodies.

In 2017, Ishan joined Sartorius Stedim Biotech as a Scientist. Ishan worked in this role until 2020, contributing to the company's scientific advancements.

Most recently, Ishan became a part of Voyager Therapeutics, Inc. in 2020. Ishan initially held the position of Scientist II and later advanced to the role of Senior Scientist I. Ishan'scurrent tenure at Voyager Therapeutics is ongoing, indicating their continued contributions to the company's research and development efforts.

Ishan Shah completed their Bachelor of Pharmacy degree at AR College of Pharmacy, Sardar Patel University from 2005 to 2009. Ishan then pursued a Master of Science in Industrial Pharmacy at The University of Toledo from 2009 to 2011. Following this, Ishan pursued a Doctor of Philosophy in Pharmaceutical Chemistry at The University of Kansas from 2011 to 2017.